Abstract
The development of checkpoint antibodies for cancer therapy has been guided by the principle of blocking T cell inhibitory signals. Recognition of the role of the Fc domain in therapeutic activities, through the depletion of immunosuppressive populations and myeloid cell activation, prompts a shift toward the development of optimized Fc-engineered checkpoint antibodies.
| Original language | English |
|---|---|
| Pages (from-to) | 501-505 |
| Number of pages | 5 |
| Journal | Trends in Molecular Medicine |
| Volume | 31 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published Online - 1 Nov 2024 |
Funding
We would like to express our gratitude to the numerous scientists in academia and industry whose work is instrumental to the field, but due to the article format constraints, their publications are not cited. The authors thank Dr. Kfir Lapid for the editorial assistance and Itai Raveh for the artwork.
All Science Journal Classification (ASJC) codes
- Molecular Medicine
- Molecular Biology